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1. Introduction 
In the later stages of dementia, more than 50% of patients will experience behavioral and 
psychological symptoms of dementia (BPSD) including psychosis (Hemels, 2001). These 
symptoms reputably cause distress in both patients and care-giving family members. 
Caregivers typically have reduced quality of life and see increases in the cost of care (Finkel, 
1997; Herrmann, 2001), whereas patients tend to increase resource utilization and form a 
high-risk group for institutionalization (Daniel, 2000). Behavioral disorders being 
paramount, it is surprising that there is little agreement on the actual description of these 
symptoms (Stoppe, 1999). This reason among others, contributes to the perception that 
“treating secondary symptoms of AD is more of an art than a science” (Corey-Bloom, 1995). 
In seeking pharmacological treatment options for psychotic symptoms in Alzheimer’s 
disease, this review will attempt to address the following four questions: 1) What is the 
definition and clinical presentation of BPSD? 2) What is the prevalence and impact of 
psychotic symptoms on the progression of dementia in AD? 3) What are the indications for 
the use of antipsychotics in the treatment of BPSD? 4) What are the evidence-based 
treatments for BPSD? 
2. Definition and clinical presentation of behavioral and psychological 
symptoms of dementia (BPSD) 
In 1996, the International Psychogeriatric Association consensus group defined behavioral 
and psychological symptoms of dementia (BPSD) as: “symptoms of disturbances of perception, 
thought content, mood or behavior frequently observed in demented patients”. 
Many classifications of BPSD have been proposed. When pharmacological treatment is 
concerned, classifying BPSD by syndromes is most useful. Although it is often difficult to 
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subgroup behavioral symptoms, psychological symptoms can be grouped into three 
syndromes: psychotic, depressive and delirious. A more descriptive classification 
summarizes the characteristic symptoms of BPSD in table 1. 
Different BPSD appear at different stages of the illness. Affective symptoms tend to appear 
in the early stages of dementia (Reisberg et al., 1989; Rubin et al., 1988), whereas psychotic 
symptoms and agitation are more frequent in patients with moderate cognitive dysfunction. 
In fact, most BPSD are present prior to the later stages of the illness, when they abate 
possibly because of the physical and neurological deterioration of the patient (Tariot & 
Blazina, 1994). 
3. Prevalence and impact of psychotic symptoms in dementia 
In a review of 30 studies of patients with AD, affective and psychotic symptoms were 
found to occur in 30%-40% of patients (Wragg & Jeste, 1989). However, up to 90% of 
patients living in institutions may suffer BPSD (Finkel, 1998). In patients with AD, the 
prevalence of psychotic symptoms alone is quite variable and was found to cluster around 
20%-40% (Raskind & Barnes, 2002). In a study following patients longitudinally from the 
beginning to the later stages of AD, presence of psychotic symptoms was documented in 
over 50% of patients, and was more common at moderate and severe stages of dementia 
(42 to 84%) (Drevets & Rubin, 1989). Furthermore, in a one year longitudinal study, 
recurrence rates of psychotic symptoms in untreated patients have been estimated at 95% 
(Levy et al., 1996). 
The two most common psychotic symptoms that develop in AD are delusions and 
hallucinations. The median prevalence of delusions is 36%, ranging between 9% and 63% 
(Ropacki and Jeste, 2005). Among the most frequent types of delusions identified are 
persecutory (involving theft) in 18-43% of patients followed by delusions of abandonment in 
3-18% and delusions of jealousy (involving infidelity) in 1-9% (Tariot & Blazina, 1994). 
Hallucinations were estimated to vary between 4-41% hallucinations with a median of 18% 
(Ropacki and Jeste, 2005). Visual hallucinations were reported in up to 30% of moderately 
demented patients, whereas auditory hallucinations may occur in up to 10% of patients 
(Swearer, 1994). Other types of hallucinations such as olfactory, tactile, gustatory and haptic 
are rarely observed (Tariot & Blazina, 1994). 
Aggression, one of the major behavioral symptoms in dementia, causes great distress in 
caregivers and can lead to earlier institutionalization (Chenoweth & Spencer, 1986; Rabins 
PV et al., 1982; Rabins et al., 1982). Delusions, mainly persecutory, have been identified as a 
risk factor for physical and verbal aggression in patients with AD (Deutsch et al., 1991). For 
instance, Deutsch et al. (1991) reported that out 181 AD patients, 43.5% suffered delusions, 
of which 29.6% were noted to be physically aggressive. Furthermore, delusions preceded 
and were significantly associated with aggressive behavior (Deutsch et al., 1991). The 
converse has also been shown in another study where 80% of patients with high levels of 
aggression (more than one episode/month) also presented with delusions (Gilley et al., 
1997). This suggests that the presence of delusions predicts the frequency of physically 
aggressive behavior. 
Increased rates of cognitive deterioration are also associated with psychotic symptoms in 
AD particularly in patients manifesting psychosis earlier in the course of dementia (Jeste et 
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al., 1992; Lopez et al., 1991; Stern et al., 1987). Interestingly, patients manifesting earlier 
psychotic symptoms were found to live longer than those without psychosis (Drevets & 
Rubin, 1989). 
4. Use of antipsychotics in the elderly 
Though outside of the official FDA indication, in the elderly, atypical antipsychotics are 
most frequently prescribed for the treatment of behavioral symptoms of dementia. In May 
2004, the FDA issued a warning of an increased death risk in elderly patients using atypical 
antipsychotics (Jeste et al., 2008). This warning was based on a meta-analysis of seventeen 
randomized double-blind controlled trials revealing a drug-related death risk increasing by 
1.6-1.7 times when compared to placebo (Jeste et al., 2008). Most frequent causes of death 
were cardiovascular (heart failure or sudden death) and infectious (pneumonia). In April 
2005, the FDA followed suit with a black box warning cautioning against the use of atypical 
antipsychotics in the elderly. Later the same year, a meta-analysis of 15 randomized 
controlled trials (Schneider et al., 2005) examined the mortality risk between placebo and 
atypical antipsychotics as well as a comparison between various atypical antipsychotics 
(aripiprazole, olanzapine, quetiapine, risperidone). This study found a small increased 
mortality risk compared to placebo (OR = 1.54; 95%CI: 1.06-2.23). No difference was found 
between antipsychotics. 
Given that this meta-analysis and the FDA warning did not apply to typical antipsychotics, 
the remaining assumption was that typical agents could be warranted in the treatment of 
BPSD. However, a study published in the New England Journal of Medicine compared the 
use of typical and atypical antipsychotics in the elderly and found that typical 
antipsychotics were associated with a significantly higher risk of death than atypical 
antipsychotics (Wang et al., 2005). Hence, typical antipsychotics should not be used to 
replace atypical agents in the treatment of BPSD. 
Currently, the FDA has not approved of any treatment for BPSD. Facing agitation in the 
elderly and consequent caregiver distress, clinicians are left with unclear choices. In the 
treatment of BPSD, what are the evidence-based alternatives? 
5. Evidence-based treatment-options for BPSD 
Non-pharmacological options 
In the treatment of BPSD, an initial assessment of the underlying causes of behavioral 
changes is necessary. Co-morbid medical illnesses and sensory impairment should be 
corrected prior to medication use. It has even been suggested that non-pharmacological 
approaches, including music therapy, light therapy, changes in stimulation, and specific 
behavioral techniques such as positive reinforcement could be attempted before medication 
(Beck & Shue, 1994; Opie et al., 1999). Although pharmacological treatment of BPSD should 
not be first line, high rates of psychotropic drug use have been reported, particularly in very 
old patients living in institutions (Giron, 2001). Between 39% and 51% of elderly 
institutionalized patients were found to be treated with antipsychotics (Avorn et al., 1989; 
Lantz et al., 1990). In the pharmacological treatment of BPSD, antipsychotic are the agents 
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that have been most frequently studied (Stoppe, 1999). In mild or moderate BPSD cases, 
particularly when symptoms are not interfering strongly with functioning, clinicians may 
opt not to treat BPSD. In such mild to moderate cases, psychosocial interventions (eg music 
therapy, cognitive therapy, behavioral management techniques, caregiver education) may 
have modest effectiveness (Cohen-Mansfield, 2001; Livingston et al, 2005).  
In severe cases where psychotic symptoms and agitation interfere with functioning and 
cause significant caregiver distress, lack of treatment may be dangerous. Below we review 
the pharmacological treatment options for BPSD. 
Antipsychotics 
A number of well-controlled trials predating the 2005 FDA warnings had examined the 
effectiveness of atypical antipsychotics in the treatment of BPSD. These studies are 
summarized and presented in Table 2. In the treatment of BPSD, atypical antipsychotics 
seem to be of significant though modest effectiveness. However, given the FDA black box 
warnings, much caution is necessary in using antipsychotics in the elderly. 
The large NIMH funded Clinical Antipsychotic Trial of Intervention Effectiveness study for 
Alzheimer's Disease (CATIE-AD) trial found that olanzapine, quetiapine, and risperidone 
were no better than placebo in the treatment of psychotic symptoms of dementia. However, 
in a review of 15 randomized controlled trials (RCTs) of atypical antipsychotics for the 
treatment of BPSD, only risperidone was found to significantly improve psychosis scores 
(Schneider et al (2006). 
Cholinesterase inhibitors 
There is some evidence supporting the relationship between cholinergic neurotransmission 
and behavioral symptoms of AD (Cummings & Kaufer, 1996). Given that neuropsychiatric 
changes in AD are associated with cholinergic deficits, one expects neuropsychiatric changes 
to respond to cholinergic therapy. Supporting this cholinergic hypothesis, Cummings 
(2000b) linked cholinergic deficits to behavior by identifying the following four dimensions 
of behavioral symptoms: “1) induction of AD-like behaviours in normal individuals by 
administration of anticholinergic drugs; 2) the exaggeration of behavioural disturbances in AD 
patients by anticholinergic agents; 3) the correlation of the distribution of cholinergic deficits of AD 
with regions that are relevant to the observed behaviours, i.e. frontal and temporal regions; and 4) 
improvement of behavioural disturbances in AD patients treated with cholinergic receptor agonists 
and cholinesterase inhibitors” (Cummings, 2000b).  
Cummings also provides some compelling evidence that cholinesterase inhibitors have 
positive psychotropic effects in AD (Cummings, 2000a). For instance, patients with 
anticholinergic delirium (agitation and psychosis) were found to be similar to AD patients 
with non-cognitive symptoms (hallucinations and agitation). Given that these symptoms 
responded well to treatment enhancing cholinergic activity (Cummings, 1993), adjusting 
acetylcholine levels can reduce psychosis. 
Displayed in table 3 are open label and double-blind studies on cholinesterase inhhibitors 
(tacrine, donepezil, metrifonate, galantamine and rivastigmine) that have found reductions 
of non-cognitive behaviors over placebo.  
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A systematic review and meta-analysis quantified the efficacy of cholinesterase inhibitors as 
a group for neuropsychiatric symptoms in patients with mild to moderate AD (Trinh et al., 
2003). This study found a modest beneficial impact on neuropsychiatric and functional 
outcomes. Other studies looking at the effects of galantamine (Hermann et al, 2005), 
donepezil (Holmes et al., 2004) and metrifonate (Kaufer, 1998) showed a modestly better 
outcome in behavioral symptoms than placebo-treated subjects. Another study compared 
memantine and placebo in AD patients treated with donepezil (Cummings et al., 2006 
Neurology). Patients treated with donepezil and memantine had better behavioral outcomes 
that those treated with donepezil and placebo. Finally, a recent pooled analysis from six 
RCTs found a small but significant benefit from memantine in behavioral outcome scores 
(Gauthier et al., 2008).  
Finally, one pilot open-label study assessed the safety of co-administration of rivastigmine 
with risperidone in dementia patients with behavioral disturbances (Weiser et al., 2002). 
The authors’ main findings were two-fold: first, both these agents could be co-
administered with no significant adverse effects and second, significant improvement in 
NPI scores were found in the rivastigmine-risperidone group of patients. These findings 
suggest that combination of these two agents might be more efficacious than either one 
alone (Weiser et al., 2002). 
6. Conclusion 
Addressing behavioral and psychological symptoms of dementia is paramount. Psychotic 
symptoms in AD occur in a majority of patients, and have a very high recurrence rate. 
Untreated BPSD can result in increased rates of hospitalization, institutionalization, cost 
of care and diminished quality of life for both patients and caregivers. Pharmacological 
treatment of BPSD should not be first line. Initial assessments of the underlying causes of 
BPSD are warranted and co-morbid medical illnesses should be corrected before initiating 
pharmacological treatment. In mild to moderate cases, non-pharmacological approaches 
(including music therapy, light therapy, changes in stimulation, and behavioral 
techniques) could be attempted before medications are used (Beck & Shue, 1994; Opie et 
al., 1999).  
Given the FDA warnings, atypical antipsychotics should only be considered in moderate to 
severe cases on a case-by-case basis after careful evaluation of the risk-benefit ratio. The 
preferred antipsychotic seems to be risperidone as it was the only agent found in a meta-
analysis of six RCTs to non-significantly increase mortality (Haupt et al., 2006) while another 
meta-analysis of fifteen trails found it to significantly improve psychosis scores (Schneider et 
al., (2006).  
Facing the paucity of safe and effective medications available, cholinesterase inhibitors may 
be used as first line pharmacotherapy. Cholinesterase inhibitors have positive psychotropic 
effects in AD and are modestly effective in the treatment of BPSD. However, many AD 
patients are taking cholinesterase inhibitors and nevertheless develop BPSD. In such cases, 
the augmentation with memantine (Cummings et al, 2006) or risperidone (Weiser et al, 2002) 
may be warranted. More studies examining the combination of cholinesterase inhibitors 
with other agents are warranted. 
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Table 1. Slassification of behavioral and psychological symptoms of dementia (BPSD). 
 
Table 2. Part I. 
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Part II 
1 - NOSIE = Nurses’ Observation Scale for Inpatient Evaluation 
2 - SCAG = Sandoz Clinical Assessment Geriatric Scale 
NPI = Neuropsychiatric Inventory, NPI-NH: Neuropsychiatric Inventory Nursing Home Version 
BEHAVE-AD = Behavioural Pathology in Alzheimer’s Disease Rating Scale 
BPRS = Brief Psychiatric Rating Scale 
CGI-S = Clinical Global Impression-Severity of Illness Scale 
NA = Not Available 
Table 2. Treatment of psychosis in AD: Atypical antipsychotics. 
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Table 3. Part I 
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Part II 
 
CIBIC-Plus: Clinician’s Interview-Based Impression of Change Plus scale 
ADAS-non-cog: Non-Cognitive portion of the Alzheimer’s Disease Assessment Scale 
Table 3. Cholinesterase inhibitors for psychosis in AD. 
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